ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics announced the grant of options to purchase 42,000 common shares to two new employees as employment inducement. The grants, approved by the Compensation Committee under the Company's Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and 1/48th monthly thereafter until full vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics ha annunciato il conferimento di opzioni per l'acquisto di 42.000 azioni ordinarie a due nuovi dipendenti come incentivo all'assunzione. I conferimenti, approvati dal Comitato per la Compensazione nell'ambito del Piano di Induzione della Società, matureranno nell'arco di quattro anni, con il 25% che si maturerà al primo anniversario e 1/48 mensilmente da quel momento fino alla maturazione completa al quarto anniversario, a condizione di mantenere il rapporto di lavoro.
ADC Therapeutics anunció la concesión de opciones para comprar 42,000 acciones ordinarias a dos nuevos empleados como un incentivo de empleo. Las concesiones, aprobadas por el Comité de Compensación bajo el Plan de Inducción de la Compañía, se consolidarán durante cuatro años, con un 25% que se consolidará en el primer aniversario y 1/48 mensualmente a partir de entonces hasta la consolidación completa en el cuarto aniversario, sujeto a la continuidad del empleo.
ADC Therapeutics는 두 명의 신규 직원에게 채용 유인으로 42,000주 일반 주식 매입 옵션을 부여했다고 발표했습니다. 이 부여는 회사의 유인 계획에 따라 보상위원회에서 승인되었으며, 4년에 걸쳐 분할되어 지급됩니다. 첫 번째 기념일에 25%가 분배되고 이후 매달 1/48씩 지급되어 네 번째 기념일에 전체 지급이 완료됩니다. 이는 계속 근무하는 것을 전제로 합니다.
ADC Therapeutics a annoncé l'octroi d'options d'achat de 42 000 actions ordinaires à deux nouveaux employés comme incitation à l'embauche. Les attributions, approuvées par le Comité de Rémunération dans le cadre du Plan d'Incitation de la Société, seront acquises sur quatre ans, avec 25% acquérant le droit au premier anniversaire et 1/48 chaque mois par la suite jusqu'à l'acquisition complète au quatrième anniversaire, sous réserve de la poursuite de l'emploi.
ADC Therapeutics gab die Gewährung von Optionen zum Kauf von 42.000 Stammaktien an zwei neue Mitarbeiter als Einstellungsmotiv bekannt. Die Gewährungen, die vom Vergütungsausschuss im Rahmen des Unternehmens-Induktionsplans genehmigt wurden, werden über vier Jahre hinweg gestaffelt, wobei 25% am ersten Jahrestag und 1/48 monatlich danach bis zur vollständigen Vesting am vierten Jahrestag fällig wird, vorausgesetzt, der Beschäftigungsverhältnis bleibt bestehen.
- Ability to attract new talent with stock-based compensation
- Implementation of structured employee retention program through four-year vesting schedule
- Potential shareholder dilution from 42,000 new stock options
The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.
The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302294232.html
SOURCE ADC Therapeutics SA
FAQ
How many stock options did ADC Therapeutics (ADCT) grant on November 1, 2024?
What is the vesting schedule for ADCT's November 2024 stock option grants?